New schizophrenia drug tested in teens for first time

NCT ID NCT02411695

Completed Symptom relief Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. Source: ClinicalTrials.gov ↗

First seen Apr 29, 2026 · Last updated May 25, 2026 · Updated 3 times

Summary

This early-stage study tested an oral medication called brexpiprazole in 43 teenagers aged 13 to 17 with schizophrenia or related disorders. The main goal was to check the drug's safety and how the body processes it, not to measure how well it works. Researchers monitored side effects, vital signs, and blood tests over about 17 days.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Study site

Little Rock, Arkansas, 72211, United States
Study site

Culver City, California, 90230, United States
Study site

Orange, California, 92858, United States
Study site

Washington D.C., District of Columbia, 20016, United States
Study site

Atlanta, Georgia, 30331, United States
Study site

Marlton, New Jersey, 08053, United States
Study site

Cincinnati, Ohio, 45219, United States
Study site

Cleveland, Ohio, 44106, United States
Study site

The Woodlands, Texas, 77381, United States
Study site

Orem, Utah, 84058, United States

Conditions

Explore the condition pages connected to this study.

SCHIZOPHRENIA